ConductScience.org, home

Paper40744833

Prostate cancer germline variants with therapeutic implications.

Bitaraf M and 2 others. Trends Mol Med, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Prostate cancer germline variants with therapeutic implications. Papers, record 40744833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40744833

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prostate cancer germline variants with therapeutic implications.
PubMed
Journal
Trends Mol Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-07-31
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bitaraf MMasoud
2Castro EElena
3Sharifi NNima

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Germ-Line MutationMajor topic
Prostatic NeoplasmsMajor topic
Humans
Male
Genetic Predisposition to Disease
BRCA2 Protein
BRCA1 Protein
Poly(ADP-ribose) Polymerase Inhibitors

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA172382NCI NIH HHSUnited StatesR01CA172382PubMed and NIHNIH RePORTER
R01 CA249279NCI NIH HHSUnited StatesR01CA249279PubMed and NIHNIH RePORTER
R01 CA261995NCI NIH HHSUnited StatesR01CA261995PubMed and NIHNIH RePORTER

Download CSV of grants

References94

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127575027HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Lancet Oncol2016https://conductscience.org/library/papers/27575027PubMed
232053149HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.JAMA Oncol2020https://conductscience.org/library/papers/32053149PubMed
339930085Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.Nat Genet2025https://conductscience.org/library/papers/39930085PubMed
431237441Clinical implications of mismatch repair deficiency in prostate cancer.Future Oncol2019https://conductscience.org/library/papers/31237441PubMed
534225539Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology.Expert Opin Ther Targets2021https://conductscience.org/library/papers/34225539PubMed
628706734BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Integr Cancer Sci Ther2017https://conductscience.org/library/papers/28706734PubMed
739052257BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.JAMA Oncol2024https://conductscience.org/library/papers/39052257PubMed
826455355Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients.Eur Urol2016https://conductscience.org/library/papers/26455355PubMed
939817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
1027070714Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.Br J Cancer2016https://conductscience.org/library/papers/27070714PubMed
1130589920Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.JAMA Oncol2019https://conductscience.org/library/papers/30589920PubMed
1223569316Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol2013https://conductscience.org/library/papers/23569316PubMed
1329439820Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.Eur Urol2018https://conductscience.org/library/papers/29439820PubMed
1423863050Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med2013https://conductscience.org/library/papers/23863050PubMed
1537966114Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.J Clin Invest2023https://conductscience.org/library/papers/37966114PubMed
1632955174Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med2020https://conductscience.org/library/papers/32955174PubMed
1729429804Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.Eur Urol2018https://conductscience.org/library/papers/29429804PubMed
18205347283beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.Endocrinology2010https://conductscience.org/library/papers/20534728PubMed
1937963304Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.J Clin Oncol2024https://conductscience.org/library/papers/37963304PubMed
2016998501The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.Oncogene2006https://conductscience.org/library/papers/16998501PubMed

See all 94 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42891338A Metabolic Cluster-Derived Risk Model for Prognostic Stratification, Immunometabolic Profiling, and Therapeutic Sensitivity Prediction in Prostate Cancer.Cancer Manag Res2026https://conductscience.org/library/papers/42891338PubMed
425182143beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer.Mol Cancer Res2026https://conductscience.org/library/papers/42518214PubMed
41763410Serendipity, steroids and science.J Steroid Biochem Mol Biol2026https://conductscience.org/library/papers/41763410PubMed
41735769Androgen metabolism in prostate cancer: recent advances.Endocrinology2026https://conductscience.org/library/papers/41735769PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
HSD3B13283PubTator's text mininghttps://conductscience.org/library/genes/3283NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40744833

GET https://conductscience.org/api/papers/v1/40744833/references?page=2